3
Participants
Start Date
July 8, 2019
Primary Completion Date
May 2, 2023
Study Completion Date
May 2, 2023
FLT190
Gene Therapy product.
Columbia University, New York
UPMC Children's Hospital of Pittsburgh, Pittsburgh
Lysosomal and Rare Disorders Research and Treatment Center, Fairfax
Kaiser Permanente, Los Angeles
Medical University of Vienna, Vienna
Charité - Universitätsmedizin Berlin, Berlin
UKEA University Hospital Hamburg, Hamburg
University of Würzburg, Würzburg
Universita Federico II di Napoli, Napoli
Haukeland University Hospital, Bergen
Royal Free Hospital, London
Salford Royal NHS Foundation Trust, Salford
Metabolics and Genetics in Calgary (MAGIC Clinic), Calgary
Lead Sponsor
Spur Therapeutics
INDUSTRY